Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Mallinckrodt
Express Scripts
Dow

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Radium ra-223 dichloride - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for radium ra-223 dichloride and what is the scope of patent protection?

Radium ra-223 dichloride is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Radium ra-223 dichloride has thirty-four patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for radium ra-223 dichloride
International Patents:34
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 30
DailyMed Link:radium ra-223 dichloride at DailyMed
Recent Clinical Trials for radium ra-223 dichloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
City of Hope Medical CenterPhase 2
National Cancer Institute (NCI)Phase 1/Phase 2
National Cancer Institute (NCI)Phase 2

See all radium ra-223 dichloride clinical trials

Pharmacology for radium ra-223 dichloride

US Patents and Regulatory Information for radium ra-223 dichloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare XOFIGO radium ra-223 dichloride SOLUTION;INTRAVENOUS 203971-001 May 15, 2013 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for radium ra-223 dichloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1140212 1490034-4 Sweden   Start Trial PRODUCT NAME: RADIUM-223; REG. NO/DATE: EU/1/13/873 20131113
1140212 92425 Luxembourg   Start Trial PRODUCT NAME: DICHLORURE DE RADOIM RA 2232 ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(XOFIGO)
1140212 507 Finland   Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Dow
Boehringer Ingelheim
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.